AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27464616 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric band with gastro-gastric suture (GGS)
Number of subjects: 706
Study 27464616 — intervention group
Group type: COMPARATOR
Intervention: Gastric band without gastro-gastric suture (no GGS)
Number of subjects: 706
Study 27464616 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index <40 kg/m at baseline
Number of subjects: 706
Study 25154831 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite comorbidity/age score
Number of subjects: 3033
Study 25154831 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥ 40 years
Number of subjects: 3033
Study 25154831 — intervention group
Group type: COMPARATOR
Intervention: High-dose conditioning regimens
Number of subjects: 3033
Study 25154831 — intervention group
Group type: COMPARATOR
Intervention: Nonmyeloablative conditioning regimens
Number of subjects: 3033
Study 25154831 — intervention group
Group type: COMPARATOR
Intervention: Age groups (20-39, 40-49, 50-59, ≥ 60)
Number of subjects: 3033
Study 22490102 — intervention group
Group type: EXPERIMENTAL
Intervention: Authentic small-group preclerkship teaching format
Number of subjects: 133
Study 22490102 — intervention group
Group type: COMPARATOR
Intervention: Non-authentic teaching formats
Number of subjects: 133
Study 22490102 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of patients seen
Number of subjects: 133
Study 20633184 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication before starting NSAID therapy
Number of subjects: 0
Study 20633184 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication alone
Number of subjects: 0
Study 20633184 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitors (PPI) therapy
Number of subjects: 0
Study 20633184 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 0
Study 19127908 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck clustered needling (acupuncture group)
Number of subjects: 76
Study 19127908 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (medication group)
Number of subjects: 76
Study 15939391 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen plugs
Number of subjects: 24
Study 15939391 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone plugs
Number of subjects: 24
Study 15939391 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 24
Study 12856384 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide gastroretentive dosage form (60 mg)
Number of subjects: 14
Study 12856384 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release tablet
Number of subjects: 14
Study 11520471 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Personality Assessment Schedule (PAS‐R)
Number of subjects: 155
Study 11520471 — intervention group
Group type: COMPARATOR
Intervention: Full version of the PAS (PAS‐I ‐ ICD version)
Number of subjects: 155
Study 8660083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (20 mg/kg/24 hours)
Number of subjects: 0
Study 8660083 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (50 mg/kg/24 hours)
Number of subjects: 0
Study 8660083 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Ibuprofen and Paracetamol
Number of subjects: 0
Study 1853990 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: exclusion and treatment of symptomatic and asymptomatic infected children
Number of subjects: 4180
Study 1853990 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: exclusion and treatment of symptomatic infection only
Number of subjects: 4180
Study 1853990 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: exclusion and treatment of symptomatic infection, treatment of asymptomatic infection in the center
Number of subjects: 4180
Study 1853990 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 4180
Study 6352281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclazindol 10‐(m‐chlorophenyl)‐2, 3, 4, 10‐tetrahydropyrimide (1, 2 alpha) indol‐10‐ol hydrochloride
Number of subjects: 0
Study 6352281 — intervention group
Group type: COMPARATOR
Intervention: Metformin 500 mg b.d.
Number of subjects: 0
Study 31626021 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodyweight exercises (including Cook hip lift)
Number of subjects: 20
Study 29952159 — intervention group
Group type: EXPERIMENTAL
Intervention: low‐flu/val: 10 mg/20 mg
Number of subjects: 20
Study 27530532 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of oral levofloxacin for 3 days
Number of subjects: 801
Study 27530532 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotics for 3 days
Number of subjects: 801
Study 25379850 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery alone
Number of subjects: 320
Study 25379850 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy + surgery
Number of subjects: 320
Study 22098272 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 1200 mg/d for 4 weeks
Number of subjects: 23
Study 22098272 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 23
Study 21286411 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention
Number of subjects: 64
Study 17602085 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 600 mg daily for 26 weeks
Number of subjects: 45
Study 16133127 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (mean daily dose of 248 mg, dose range 50-450 mg)
Number of subjects: 0
Study 16133127 — intervention group
Group type: COMPARATOR
Intervention: Selective serotonin re-uptake inhibitors (SSRIs)
Number of subjects: 0
Study 12930173 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (STR)
Number of subjects: 18
Study 12930173 — intervention group
Group type: COMPARATOR
Intervention: Nonstretching (NSTR)
Number of subjects: 18
Study 10373865 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter removal at 2400 hours (group A)
Number of subjects: 48
Study 10373865 — intervention group
Group type: COMPARATOR
Intervention: Catheter removal at 0600 hours (group B)
Number of subjects: 48
Study 8679358 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine 0.15 mg kg‐1
Number of subjects: 19
Study 8679358 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine 0.30 mg kg‐1
Number of subjects: 19
Study 8679358 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 1651993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 2531
Study 1651993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based therapy
Number of subjects: 2531
Study 1651993 — intervention group
Group type: EXPERIMENTAL
Intervention: Good PS with hemoglobin level >= 11 g/dL and age > 47 years
Number of subjects: 2531
Study 1651993 — intervention group
Group type: COMPARATOR
Intervention: Good PS
Number of subjects: 2531
Study 1651993 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin level >= 11.0 g/dL, normal LDH, normal calcium, single metastatic site
Number of subjects: 2531
Study 7038553 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg UDPG
Number of subjects: 2
Study 7038553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 30943958 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Circles intervention (10 sessions co-designed and facilitated by circle leaders)
Number of subjects: 155
Study 30943958 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Circles intervention
Number of subjects: 155
Study 30943958 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Circles intervention (more sessions attended)
Number of subjects: 155
Study 30943958 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 155
Study 29029679 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 248
Study 29029679 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation and supportive therapy (PST)
Number of subjects: 248
Study 29029679 — intervention group
Group type: COMPARATOR
Intervention: Behavior therapy and PST
Number of subjects: 248
Study 25644279 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir 25 mg plus paritaprevir/ritonavir 100/100 mg or 150/100 mg for 12 or 24 weeks (subtype 1b)
Number of subjects: 110
Study 25644279 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir 25 mg plus paritaprevir/ritonavir 100/100 mg for 12 weeks (genotype 2)
Number of subjects: 110
Study 25644279 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir 25 mg plus paritaprevir/ritonavir 100/100 mg or 150/100 mg (genotype 2)
Number of subjects: 110
Study 25644279 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Number of subjects: 110
Study 24477392 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with 15 sessions at a dosage of 18 J per session over the carpal tunnel area with neutral wrist splint
Number of subjects: 66
Study 24477392 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser therapy with neutral wrist splint
Number of subjects: 66
Study 22468576 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavior therapy for psychosis (CBTp)
Number of subjects: 0
Study 22468576 — intervention group
Group type: COMPARATOR
Intervention: Group social skills training
Number of subjects: 0
Study 22468576 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 18930200 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation group (injection of culture medium)
Number of subjects: 144
Study 18930200 — intervention group
Group type: EXPERIMENTAL
Intervention: SEET group (injection of embryo culture supernatant)
Number of subjects: 144
Study 18930200 — intervention group
Group type: COMPARATOR
Intervention: BT group (control)
Number of subjects: 144
Study 17098835 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone 100 mg three times daily
Number of subjects: 677
Study 17098835 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 677
Study 10916805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory cataract surgery
Number of subjects: 44
Study 10916805 — intervention group
Group type: COMPARATOR
Intervention: Inpatient cataract surgery
Number of subjects: 44
Study 8737616 — intervention group
Group type: EXPERIMENTAL
Intervention: Gn-RH-a for 3 months
Number of subjects: 36
Study 8737616 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 36
Study 8737616 — intervention group
Group type: COMPARATOR
Intervention: Nothing
Number of subjects: 36
Study 1443864 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (24 micrograms)
Number of subjects: 0
Study 1443864 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone (200 micrograms)
Number of subjects: 0
Study 1443864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1443864 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control inhalation)
Number of subjects: 0
Study 3840660 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (n=46)
Number of subjects: 66
Study 3840660 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane (n=43)
Number of subjects: 66
Study 3840660 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (n=35)
Number of subjects: 66
Study 3840660 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 66
Study 3840660 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 66
Study 31719087 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention from a certified peer recovery support specialist
Number of subjects: 650
Study 31719087 — intervention group
Group type: COMPARATOR
Intervention: Behavioural intervention from a licensed clinical social worker (LCSW)
Number of subjects: 650
Study 30185197 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach visits (15 to 20 minutes per guideline)
Number of subjects: 239
Study 30185197 — intervention group
Group type: COMPARATOR
Intervention: Passive guideline dissemination (access to guidelines via website)
Number of subjects: 239
Study 26589241 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with persistent albuminuria (15.8%)
Number of subjects: 502
Study 26589241 — intervention group
Group type: COMPARATOR
Intervention: Participants without albuminuria
Number of subjects: 502
Study 26589241 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with intermittent albuminuria
Number of subjects: 502
Study 26589241 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline albuminuria
Number of subjects: 502
Study 26589241 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent albuminuria
Number of subjects: 502
Study 23978408 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits with calls
Number of subjects: 610
Study 23978408 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone calls only
Number of subjects: 610
Study 23978408 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo calls)
Number of subjects: 610
Study 23978408 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits and calls combined
Number of subjects: 610
Study 23978408 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (home, call, control)
Number of subjects: 610
Study 23978408 — intervention group
Group type: EXPERIMENTAL
Intervention: Study groups (home and call)
Number of subjects: 610
Study 22647925 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0‐mm 3‐dimensional miniplate (group A)
Number of subjects: 50
Study 22647925 — intervention group
Group type: COMPARATOR
Intervention: 2.0‐mm conventional miniplate (group B)
Number of subjects: 50
Study 19924399 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation-assisted gap balancing
Number of subjects: 116
Study 19924399 — intervention group
Group type: COMPARATOR
Intervention: Conventional measured resection
Number of subjects: 116
Study 18450803 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of vancomycin (25 mg/kg/day or 15 mg/kg/day in period 1; 30 mg/kg/day or 20 mg/kg/day in period 2)
Number of subjects: 145
Study 15930039 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful thrombolysis
Number of subjects: 362
Study 15930039 — intervention group
Group type: COMPARATOR
Intervention: Rescue PTCA
Number of subjects: 362
Study 12501480 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitors of cholinesterase plus selective serotonin reuptake inhibitors (SSRIs) (citalopram HBr, 20 mg/day)
Number of subjects: 50
Study 12501480 — intervention group
Group type: COMPARATOR
Intervention: Inhibitors of cholinesterase (Donepezil, 5 mg/day)
Number of subjects: 50
Study 10607980 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behaviour Therapy (CBT)
Number of subjects: 121
Study 10607980 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 121
Study 7495344 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic sclerosis patients
Number of subjects: 48
Study 7495344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery systolic hypertension alone
Number of subjects: 48
Study 7495344 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic hypertension alone
Number of subjects: 48
Study 7495344 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pulmonary and systemic hypertension
Number of subjects: 48
Study 7495344 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal pulmonary artery and systemic pressures
Number of subjects: 48
Study 2029996 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.15 mg/kg)
Number of subjects: 20
Study 2029996 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline, 0.3 ml/kg)
Number of subjects: 20
Study 31999480 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint odor stimulation
Number of subjects: 60
Study 31999480 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory takeover modality
Number of subjects: 60
Study 31999480 — intervention group
Group type: COMPARATOR
Intervention: Tactile takeover modality
Number of subjects: 60
Study 31999480 — intervention group
Group type: COMPARATOR
Intervention: Placebo (air)
Number of subjects: 60
Study 31013009 — intervention group
Group type: EXPERIMENTAL
Intervention: H9N2-specific antibody detection
Number of subjects: 80
Study 28488353 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized management programme comprising nurse-led education and review of care plans by stroke specialists in addition to usual care
Number of subjects: 563
Study 28488353 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 563
Study 26154851 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mcg of EE + DRSP
Number of subjects: 44
Study 26154851 — intervention group
Group type: COMPARATOR
Intervention: 20 mcg of EE + DRSP
Number of subjects: 44
Study 23642945 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee venom acupuncture point injection (0.005% diluted in normal saline, 0.05 ml at each point, twice-weekly for three weeks)
Number of subjects: 16
Study 23642945 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group, twice-weekly for three weeks)
Number of subjects: 16
Study 22121857 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 2 months
Number of subjects: 80
Study 22121857 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 80
Study 21029347 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily for 4 weeks
Number of subjects: 60
Study 21029347 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo for 4 weeks
Number of subjects: 60
Study 17379122 — intervention group
Group type: EXPERIMENTAL
Intervention: Trachlight (TL)
Number of subjects: 60
Study 17379122 — intervention group
Group type: COMPARATOR
Intervention: GlideScope (GS)
Number of subjects: 60
Study 15613678 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of A2 allele
Number of subjects: 1257
Study 11875051 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP1 G‐1607GG allele
Number of subjects: 590
Study 11875051 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotypes of MMP1 G‐1607GG and MMP12 Asn357Ser
Number of subjects: 590
Study 9790160 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (37.5 mg daily increasing up to 225 mg daily)
Number of subjects: 17
Study 8669887 — intervention group
Group type: EXPERIMENTAL
Intervention: FEMP + PSK
Number of subjects: 227
Study 8669887 — intervention group
Group type: EXPERIMENTAL
Intervention: FEMP + LMS
Number of subjects: 227
Study 8669887 — intervention group
Group type: COMPARATOR
Intervention: FEMP
Number of subjects: 227
Study 2212186 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 121
Study 2212186 — intervention group
Group type: COMPARATOR
Intervention: Non-directive psychotherapy
Number of subjects: 121
Study 2212186 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 121
Study 2212186 — intervention group
Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 121
Study 2212186 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 121
Study 475947 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated prednisolone tablets (shellac based)
Number of subjects: 0
Study 475947 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated prednisolone tablets (cellulose acetate phthalate based)
Number of subjects: 0
Study 475947 — intervention group
Group type: COMPARATOR
Intervention: Plain prednisolone
Number of subjects: 0
Study 31416771 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐health and telephone group (e‐HT)
Number of subjects: 65
Study 31416771 — intervention group
Group type: COMPARATOR
Intervention: telephone only group (TO)
Number of subjects: 65
Study 30915462 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab treatment for 52 weeks
Number of subjects: 20
Study 29086522 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine with Wi-Fi scales, text messaging (texting)
Number of subjects: 196
Study 29086522 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine with Wi-Fi scales
Number of subjects: 196
Study 29086522 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 196
Study 29086522 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging (texting)
Number of subjects: 196
Study 25467560 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir (100 mg) plus Elbasvir (20 mg or 50 mg) for 12 weeks without ribavirin
Number of subjects: 218
Study 25467560 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir (100 mg) plus Elbasvir (20 mg or 50 mg) for 12 weeks with ribavirin
Number of subjects: 218
Study 25467560 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir (100 mg) plus Elbasvir (50 mg) for 8 weeks without ribavirin
Number of subjects: 218
Study 25467560 — intervention group
Group type: COMPARATOR
Intervention: Grazoprevir (100 mg) plus Elbasvir (50 mg) for 12 weeks
Number of subjects: 218
Study 23414745 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity muscle strength training of the quadriceps and hamstrings using an isokinetic dynamometer (20 to 30% of peak torque)
Number of subjects: 32
Study 23414745 — intervention group
Group type: COMPARATOR
Intervention: Aerobic-type training with a cycle ergometer
Number of subjects: 32
Study 22179158 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical exercise (65-75% HR(max)) for 30 minutes
Number of subjects: 10
Study 22179158 — intervention group
Group type: COMPARATOR
Intervention: Control session (no exercise)
Number of subjects: 10
Study 19545446 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice nurse-led collaborative care
Number of subjects: 900
Study 19545446 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 900
Study 16800964 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 731
Study 15553108 — intervention group
Group type: EXPERIMENTAL
Intervention: Test tablet (levothyroxine sodium tablets 200 microg; Eferox)
Number of subjects: 25
Study 15553108 — intervention group
Group type: COMPARATOR
Intervention: Reference tablet
Number of subjects: 25
Study 15553108 — intervention group
Group type: COMPARATOR
Intervention: Oral solution
Number of subjects: 25